Versant Venture Capital VI, L.P. 13D/13G Filings for Akero Therapeutics, Inc. (AKRO)

Versant Venture Capital VI, L.P. 13D and 13G filings for Akero Therapeutics, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		 Transaction
Date		 Type Company
Symbol		 Filed By
Symbol		 Shares Owned
% Owned		 Shares Vs. Prev Report View
2021-02-12
8:41 pm
Sale		 2020-12-31 13G Akero Therapeutics, Inc.
AKRO		 Versant Venture Capital VI, L.P. 777,727
2.200%		 -2,878,858decrease
(-78.73%)		 Filing